OINDPnews


Proveris Scientific

Business

Armstrong advises customers to stock up on Primatene Mist

Armstrong Pharmaceuticals is advising customers to stockpile its Primatene Mist epinephrine MDI before the FDA ban on CFC formulations takes effect on December 31, 2011. The company says that it is "actively finalizing its internal development" of an HFA formulation but warns that there is likely to be a period of time after the ban goes into effect before the new … [Read more...] about Armstrong advises customers to stock up on Primatene Mist

US sales of Cayston double

A small portion of Gilead's 11% increase in revenue for the second quarter of 2011 compared to the same quarter in 2010 is attributable to a 105% increase in the US sales of Cayston astreonam inhalation solution over that period. The company's revenues for the quarter totaled $2.14 billion. Sales of Cayston for the treatment of P. aeruginosa infections in cystic … [Read more...] about US sales of Cayston double

Aradigm gets additional funding from existing shareholders

Existing shareholders have agreed to purchase additional Aradigm Corporation common stock for a total of $4.75 million. The three shareholders will pay $0.19 per share for 25 million shares. The net proceeds for Aradigm after fees and expenses should be about $4.4 million. "We are very pleased for the support demonstrated by our shareholders in this private … [Read more...] about Aradigm gets additional funding from existing shareholders

Pearl heading into new Phase 2 studies for COPD combination inhaler

Pearl Therapeutics is advancing its PT003 combination inhaler for COPD, and the products individual components, into a new series of Phase 2 trials in patients with moderate-to-severe COPD. The individual compounds are PT001, glycopyrrolate, and PT005, their formoterol fumarate. The Phase 2 studies include randomized, double-blind studies of PT001 compared to … [Read more...] about Pearl heading into new Phase 2 studies for COPD combination inhaler

Mystic Pharmaceuticals receives patent for intranasal drug packaging technology

The “Deep Draw Container Forming Method” developed by Mystic Pharmaceuticals for packaging of intranasal drugs for use with its VersiDoser and VRx2 intranasal delivery systems has been awarded US Patent No. 7,963,089. Both delivery systems use the proprietary unit dose blister packaging. The VersiDoser uses liquid-filled blisters, while the VRx2 reconstitutes freeze … [Read more...] about Mystic Pharmaceuticals receives patent for intranasal drug packaging technology

Generex reboots buccal insulin spray development program

After receiving written guidance from the FDA in late May, says Generex, it has revised its development program for its Oral-lyn buccal insulin spray. A reorganized medical/regulatory group within the company will focus its efforts on providing information requested by the agency regarding the product's "preclinical, clinical, toxicology, manufacturing, and regulatory … [Read more...] about Generex reboots buccal insulin spray development program